GlaxoSmithKline (LON:GSK) Stock Rating Reaffirmed by Barclays
Other equities analysts have also recently issued reports about the company. Citigroup restated a neutral rating on shares of GlaxoSmithKline in a research report on Thursday, November 7th. Goldman Sachs Group set a GBX 1,900 ($24.83) target price on GlaxoSmithKline and gave the stock a buy rating in a research report on Wednesday, October 30th. Credit Suisse Group boosted their target price on GlaxoSmithKline from GBX 1,700 ($22.21) to GBX 1,800 ($23.52) and gave the stock a neutral rating in a research report on Thursday, October 31st. HSBC restated a buy rating and set a GBX 2,110 ($27.57) target price on shares of GlaxoSmithKline in a research report on Tuesday, October 1st. Finally, DZ Bank boosted their target price on GlaxoSmithKline from GBX 1,850 ($24.17) to GBX 2,000 ($26.13) and gave the stock a buy rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of GBX 1,763.67 ($23.05).
GlaxoSmithKline stock traded up GBX 2.20 ($0.03) during midday trading on Monday, hitting GBX 1,716.40 ($22.43). 7,307,511 shares of the company’s stock were exchanged, compared to its average volume of 9,120,000. GlaxoSmithKline has a 52-week low of GBX 1,408.80 ($18.41) and a 52-week high of GBX 1,796.40 ($23.47). The stock has a 50-day moving average price of GBX 1,706.44 and a two-hundred day moving average price of GBX 1,642.22. The company has a debt-to-equity ratio of 183.00, a quick ratio of 0.50 and a current ratio of 0.82. The company has a market cap of $84.01 billion and a P/E ratio of 18.80.
In other news, insider Vivienne Cox purchased 308 shares of the company’s stock in a transaction on Wednesday, October 30th. The stock was purchased at an average price of GBX 1,725 ($22.54) per share, with a total value of £5,313 ($6,942.38). In the last ninety days, insiders have acquired 330 shares of company stock valued at $568,756.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Read More: Investing in Dividend Stocks
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.